Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurosci Res. 2008 Mar;86(4):904-9.

Novel lipoxygenase inhibitors as neuroprotective reagents.

Author information

1
Neuroprotection Research Laboratory, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA. klaus_vanleyen@hms.harvard.edu

Abstract

The lipid-metabolizing enzyme 12/15-lipoxygenase (12/15-LOX) mediates cell death resulting from oxidative stress in both neurons and oligodendrocytes. Specifically, it may contribute to the pathophysiology of stroke and Alzheimer's and Parkinson's diseases. We report here that two of three specific 12/15-LOX inhibitors, derived from a virtual screen by computer modeling and validated by inhibition of recombinant human 15-LOX in vitro, are able to rescue both neuronal as well as oligodendroglial cells from cell death induced by oxidative stress. Thus, in a fairly streamlined process, an initial virtual screen of 50,000 compounds in a library of drug-like molecules has led to the identification of two novel drug candidates for targeting LOX. Future studies of these novel neuroprotective inhibitors of 12/15-LOX may provide new therapeutic opportunities to combat stroke and other neurodegenerative diseases.

PMID:
17960827
PMCID:
PMC2759176
DOI:
10.1002/jnr.21543
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center